November 25, 2025 — Leads & Copy —
PETACH TIKVA, Israel — PolyPid Ltd. (Nasdaq: PYPD) will participate in a virtual Key Opinion Leader (KOL) event hosted by ROTH Capital Partners on Wednesday, December 10, 2025, at 11:30 AM Eastern Time, according to a press release issued November 25, 2025.
The Key Opinion Leader (KOL) event is a webinar titled, “The Science and Business Case for D-PLEX100 (Tackling Surgical Site Infections).”
The event will feature Steven D. Wexner, MD, FACS, FRCS (Eng), FRCS(Ed), FRCSI (Hon), Hon FRCS (Glasg), Hon FRCS (Eng), MAMSE, Executive Director and System Chief for Colorectal Surgery, and Professor and Vice Chair, Department of Surgery, MedStar Georgetown University Hospital, Washington, DC.
Dr. Wexner will discuss the clinical and economic burden of surgical site infections (SSIs), current prevention strategies and their limitations, and the potential role of D-PLEX100 in addressing this unmet medical need in abdominal colorectal surgery and other surgical settings.
Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at ROTH Capital Partners, will host and moderate the discussion. A live question-and-answer session with Dr. Wexner and PolyPid’s management team will follow the formal presentation.
Dr. Wexner is an internationally recognized pioneer in colorectal surgery with over 38 years of clinical, academic and research experience. He specializes in surgery for rectal cancer, inflammatory bowel disease, rectourethral and rectovaginal fistulas, and complex re-operative pelvic surgery.
He has held leadership roles in surgical societies, including the American Society of Colon and Rectal Surgeons, the American Board of Colon and Rectal Surgery, and the Society of American Gastrointestinal and Endoscopic Surgeons. With more than 1,200 publications and over 43,000 citations, Dr. Wexner has trained hundreds of surgeons globally through his clinical practice, research and education activities.
PolyPid’s lead product candidate, D-PLEX₁₀₀, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs).
The PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site.
D-PLEX₁₀₀ recently demonstrated positive results in the Phase 3 SHIELD II trial, achieving a statistically significant 58% (p< 0.005) relative risk reduction in SSI incidence following abdominal colorectal surgery with large incisions. It has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery.
PolyPid is a late-stage biopharma company aiming to improve surgical outcomes. The company’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months.
PolyPid’s New Drug Application (NDA) submission of D-PLEX₁₀₀, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. The Company also has an innovative pipeline in oncology, obesity and diabetes.
Registration for the KOL event can be found at: https://roth.zoom.us/webinar/register/WN_yP7JWS3xSrqCaDQTwGazyA#/registration
Company Contact:
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor Relations Contact:
North American Equities Desk
polypid@arxhq.com
Source: PolyPid Ltd.
